Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBRX 
Forte Biosciences Inc (FBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: FBRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $52.25
1 Year Target Price $52.25
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.35% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.07M USD | Price to earnings Ratio - | 1Y Target Price 52.25 |
Price to earnings Ratio - | 1Y Target Price 52.25 | ||
Volume (30-day avg) 4 | Beta 3.3 | 52 Weeks Range 4.90 - 28.68 | Updated Date 11/24/2025 |
52 Weeks Range 4.90 - 28.68 | Updated Date 11/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.08 | Actual -0.99 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.79% | Return on Equity (TTM) -73.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 139085913 | Price to Sales(TTM) - |
Enterprise Value 139085913 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.87 | Shares Outstanding 12432854 | Shares Floating 10221049 |
Shares Outstanding 12432854 | Shares Floating 10221049 | ||
Percent Insiders 4.97 | Percent Institutions 87.95 |
Upturn AI SWOT
Forte Biosciences Inc
Company Overview
History and Background
Forte Biosciences, Inc., founded in 2017, focused on developing novel therapies for autoimmune diseases. It initially centered on FB-401, a live biotherapeutic for atopic dermatitis. The company later pivoted and then merged with a subsidiary of Cassava Sciences in 2024.
Core Business Areas
- Dermatology: Forte Biosciences initially focused on FB-401, a live biotherapeutic targeting atopic dermatitis. This included research, clinical trials, and potential commercialization efforts.
Leadership and Structure
As of early 2024, Paul Wagner was the CEO. Post merger, the leadership and structure changed under Cassava Sciences (SAVA).
Top Products and Market Share
Key Offerings
- FB-401 (formerly): FB-401 was Forte's primary asset, a live biotherapeutic for atopic dermatitis. It did not achieve commercialization and possessed no market share. Key competitors in the atopic dermatitis market include companies with approved therapies like Dupixent (Sanofi/Regeneron).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the dermatology and autoimmune disease sectors, is characterized by high research and development costs, regulatory hurdles, and intense competition.
Positioning
Before the merger, Forte Biosciences was a smaller player trying to gain traction in the competitive dermatology market.
Total Addressable Market (TAM)
The global atopic dermatitis market was estimated to be in the billions of dollars annually. Forte was trying to capture a portion with FB-401 before the merger.
Upturn SWOT Analysis
Strengths
- Novel live biotherapeutic approach (FB-401)
- Experienced management team (prior to the pivot)
- Strong intellectual property portfolio (related to FB-401)
Weaknesses
- Reliance on a single product candidate (FB-401)
- Lack of commercialized products
- Limited financial resources
- Unproven efficacy of FB-401 in pivotal trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other autoimmune diseases
- Positive clinical trial results for FB-401 or other candidates
- Advancements in microbiome research
Threats
- Failure of clinical trials
- Regulatory setbacks
- Competition from established therapies
- Patent challenges
- Lack of funding
Competitors and Market Share
Key Competitors
- SNY
- REGN
- BMY
- MRK
Competitive Landscape
Before the merger, Forte Biosciences faced significant disadvantages compared to larger, more established pharmaceutical companies with approved therapies and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was minimal, primarily reflecting growth in research and development activities.
Future Projections: Future projections for Forte are no longer relevant as the company merged with a subsidiary of Cassava Sciences.
Recent Initiatives: The most recent strategic initiative was the merger with a subsidiary of Cassava Sciences (SAVA) which refocused the companies goals and direction.
Summary
Forte Biosciences faced significant hurdles in the competitive biopharmaceutical industry, primarily due to its reliance on a single unproven product and limited financial resources. The merger with a subsidiary of Cassava Sciences represents a strategic shift. Prior to this merger, Forte's success hinged on the success of FB-401's clinical trials and its ability to secure partnerships or funding. The company needed to carefully manage its cash reserves and navigate the regulatory landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information presented is accurate to the best of our knowledge as of the current date. The data is based on public information prior to the merger and recent activity of the organization.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forte Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2017-04-13 | CEO, President & Chairman Dr. Paul A. Wagner Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.fortebiorx.com |
Full time employees 16 | Website https://www.fortebiorx.com | ||
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.